Table 1.
Pulsatile | 121 (77.6%) |
Abiomed AB 5000 | 6 (3.8%) |
Novacor | 43 (27.6%) |
HeartMate XVE | 33 (21.2%) |
Thoratec IVAD | 6 (3.8%) |
Thoratec PVAD | 33 (21.2%) |
* Continuous Flow | 35 (22.4%) |
HeartMate II | 15 (9.6%) |
JARVIK 2000 | 2 (1.3%) |
Ventrassist | 18 (11.5%) |
Total | 156 |
lists the number (percentage) of patients with initial continuous-flow LVAD in RVAD− group.